Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ANO1 | Q5XXA6 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.43 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24713929 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2POLBCSNK1DMEN1KMT2A | |
| SCHEMBL25144073 | 0.81 | ANO1 (0.62) | ANO1POLB | |
| SCHEMBL23362766 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2POLBCSNK1DMEN1KMT2A | |
| SCHEMBL30296102 | 0.80 | SMN1; SMN2 (0.52) | SMN1; SMN2POLBCSNK1DMEN1KMT2A | |
| SCHEMBL24714070 | 0.79 | MEN1 (0.53) | SMN1; SMN2LMNAANO1POLBCSNK1D | |
| SCHEMBL21198339 | 0.78 | ANO1 (0.80) | ANO1 | |
| SCHEMBL31306577 | 0.78 | ANO1 (0.80) | ANO1 | |
| SCHEMBL6343545 | 0.78 | HSD17B10 (0.70) | SMN1; SMN2LMNAMEN1KMT2ATSHR | |
| SCHEMBL10864128 | 0.78 | CYP3A4 (0.62) | SMN1; SMN2L3MBTL1POLBMEN1KMT2A | |
| SCHEMBL29431167 | 0.78 | HSD17B10 (0.70) | SMN1; SMN2LMNAMEN1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230118751-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | P2RX4, P2RX3, P2RX2 | SMN1; SMN2 2862/4885LMNA 4315/4885L3MBTL1 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.